- Company
- Will Paxlovid open a market for elderly people’s benefits?
- by Eo, Yun-Ho Oct 16, 2023 05:24am
- As the sense of crisis regarding COVID-19 infection is decreasing, attention is being paid to whether Paxlovid, a treatment drug, can successfully be registered for insurance benefits. Pfizer Korea is currently proceeding with the registration process for Paxlovid, which has been approved as an oral treatment for COVID-19, with the goal of l
- Company
- Bayer Korea appoints JinA Lee as new Managing Director
- by Eo, Yun-Ho Oct 13, 2023 05:29am
- Bayer Korea appointed JinA Lee (54) as the new Managing Director. With this appointment, Lee will become the first Korean head to be appointed to the establishment of Bayer Korea. The company recently announced through an internal announcement that it will appoint JinA Lee, former CDH (Country Division Head) of Pharmaceuticals and Managin
- Company
- Companies entering the Middle East caught in the crossfire
- by Kim, Jin-Gu Oct 12, 2023 05:38am
- On the 7th (local time), the Palestinian armed political faction Hamas attacked Israel (CNN photo). As the situation in Israel and nearby regions has deteriorated rapidly due to large-scale airstrikes by the Palestinian armed political faction Hamas, domestic pharmaceutical and bio companies that have entered or are seeking to enter the Midd
- Company
- Bukwang Pharm’s Ozanex lands in major general hospitals
- by Nho, Byung Chul Oct 12, 2023 05:37am
- Bukwang Pharm announced that its new topical antibiotic Ozanex cream(ozenoxacin)’ recently passed the drug committee of Seoul St.Mary’s Hospital and can be prescribed in major general hospitals in Korea. Ozanex, a topical antibiotic that Bukwang was first to introduce to Korea, is currently being prescribed at various major general hosp
- Company
- Pricing negotiations for Koselugo’s reimb start after 2 yrs
- by Eo, Yun-Ho Oct 11, 2023 05:36am
- Koselugo, which is a treatment for pediatric patients with neurofibromatosis, has entered its last gateway to receiving reimbursement in Korea. According to industry sources, AstraZeneca has recently started drug pricing negotiations with the National Health Insurance Service to set the insurance price for its new neurofibromatosis drug,
- Company
- Trajenta, unregistered patent challenge spreads
- by Kim, Jin-Gu Oct 10, 2023 05:27am
- Challenges to Trajenta's unlisted patents have expanded further. The number of patents targeted by generic companies increased from 8 to 11. According to the pharmaceutical industry on the 5th, Kukje Pharmaceutical recently requested a passive rights scope confirmation trial for three Trajenta-Duo formulation patents. These three formulation
- Company
- Disadvantages of effective ADC anticancer drugs
- by Oct 10, 2023 05:27am
- It has been shown that patient accessibility to antibody-drug conjugates (ADCs) introduced in Korea has been significantly reduced due to high non-reimbursed drug prices. The price of non-reimbursed Trodelvy, which was approved in Korea last May, is about 1.6 million won per vial. Converted into one cycle (21 days, 2 administrations), the cost i
- Company
- GSK’s momelotinib receives orphan drug designation in KOR
- by Eo, Yun-Ho Oct 10, 2023 05:26am
- The new myelofibrosis drug momelotinib has been designated as an orphan drug in Korea. The Ministry of Food and Drug Safety announced so through an orphan drug designation notice issued on the 6th. Momelotinib is a treatment for myelofibrosis that blocks the major signaling pathways for JAK1, JAK2, and activin A receptor type 1 (ACVR1)
- Company
- Hemgenix receives orphan drug designation in KOR
- by Eo, Yun-Ho Oct 10, 2023 05:26am
- The one-shot gene therapy for hemophilia, Hemgenix, has been designated as an orphan drug in Korea. On the 6th, the Ministry of Food and Drug Safety announced so through an orphan drug designation notice. Hemgenix (etranacogene dezaparvovec-drlb), which is the first and only one-time gene therapy approved for the treatment of adults li
- Company
- Dongkook succeeds P3T for its BPH combination drug
- by Chon, Seung-Hyun Oct 6, 2023 05:37am
- On September 25th, Dongkook Pharmaceutical announced that it had confirmed the safety and efficacy of its incrementally modified combination drug for benign prostatic hyperplasia (BPH), ‘DKF-313,’ through a Phase III trial. Based on the positive results, Dongkook Pharmaceutical plans to complete the Phase III trial result report within the
